Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ardelyx Inc ARDX

Healthcare Biotechnology
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control... see more

Recent & Breaking News (NDAQ:ARDX)

Ardelyx to Present at the Jefferies 2022 Healthcare Conference

PR Newswire June 3, 2022

Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

PR Newswire May 24, 2022

Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022

PR Newswire May 17, 2022

Ardelyx, Inc. Reports Employment Inducement Grants

PR Newswire May 16, 2022

Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights

PR Newswire May 5, 2022

Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

GlobeNewswire May 2, 2022

Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022

PR Newswire April 28, 2022

Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)

PR Newswire April 25, 2022

Ardelyx, Inc. Reports Employment Inducement Grants

PR Newswire April 12, 2022

Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor

PR Newswire April 11, 2022

Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings

PR Newswire April 7, 2022

Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults

PR Newswire April 4, 2022

Ardelyx, Inc. Reports Employment Inducement Grants

PR Newswire March 9, 2022

Ardelyx to Participate at the Cowen 42nd Annual Health Care Conference

PR Newswire March 2, 2022

Ardelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

PR Newswire February 28, 2022

Ardelyx Announces $27.5 Million Debt Financing Agreement with SLR Capital Partners

PR Newswire February 24, 2022

Ardelyx to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

PR Newswire February 22, 2022

Ardelyx, Inc. Reports Employment Inducement Grants

PR Newswire February 4, 2022

ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Business Wire December 10, 2021

Ardelyx Launching IBSRELA® Second Quarter of 2022

PR Newswire November 30, 2021